Uchiyama Y, Takamori H, Miyama K, Takano E, Nakajima H, Sato T, Nakamura T
New Product Research Laboratories III, Daiichi Pharmaceutical Co., Ltd., 1-16-13, Kita-Kasai Endogawa-ku, Tokyo-134, Japan.
Calcif Tissue Int. 1998 Jun;62(6):519-26. doi: 10.1007/s002239900472.
To assess the reductions in bone mass, strength, and turnover in adjuvant-induced arthritic rats and to examine the effect of a new benzamide compound, DU-6712, on these parameters, a 28-day dosing experiment was performed using 8-week-old female Lewis rats. Arthritis was induced by injecting the adjuvant into the hind paw. The age-dependent increases in the body weight, lumbar bone mineral content and density (BMC and BMD) and compressive strength were disturbed in the arthritic rats. At 14 days, the histomorphometric parameters of bone formation (BFR/BS and BFR/BV) and the serum osteocalcin levels were significantly reduced compared with the baseline controls. However, the BMC values corrected for body weight did not differ significantly between the arthritic and normal rats, and the bone minerals were not reduced compared with the baseline controls. At 28 days, the parameters of bone minerals and strength of the lumbar body in the arthritic rats, both with and without correction for body weight, were significantly reduced compared with the baseline controls. The trabecular mineralizing surface remained significantly reduced and the osteoclast numbers were increased. DU-6712 at the doses of 5, 15, and 45 mg/kg, orally administered daily from the start of the experiment, significantly prevented the development of the chronic paw edema at 28 days. The reductions in the parameters of bone minerals, strength, and trabecular bone formation, and the increase in osteoclast number were alleviated by this agent. Age-dependent increases in the lumbar height, disturbed by the adjuvant injection, were also maintained. These data indicated that a 28-day period is necessary to obtain sufficient reductions in the bone mass and strength of the lumbar body concerning the model of secondary osteoporosis in adjuvant arthritic rats. DU-6712 was able to prevent these reductions by modulating the bone turnover in this arthritis model.
为评估佐剂诱导的关节炎大鼠的骨量、骨强度和骨转换的降低情况,并研究一种新型苯甲酰胺化合物DU - 6712对这些参数的影响,使用8周龄雌性Lewis大鼠进行了为期28天的给药实验。通过将佐剂注射到后爪诱导关节炎。关节炎大鼠体重、腰椎骨矿物质含量和密度(BMC和BMD)以及抗压强度随年龄的增加受到干扰。在第14天,与基线对照组相比,骨形成的组织形态计量学参数(BFR/BS和BFR/BV)以及血清骨钙素水平显著降低。然而,经体重校正后的BMC值在关节炎大鼠和正常大鼠之间没有显著差异,并且与基线对照组相比骨矿物质没有减少。在第28天,与基线对照组相比,关节炎大鼠腰椎体的骨矿物质和强度参数,无论是否经体重校正,均显著降低。小梁矿化表面仍显著减少,破骨细胞数量增加。从实验开始每天口服给予5、15和45 mg/kg剂量的DU - 6712,可显著预防28天时慢性爪水肿的发展。该药物减轻了骨矿物质、强度和小梁骨形成参数的降低以及破骨细胞数量的增加。佐剂注射所干扰的腰椎高度随年龄的增加也得以维持。这些数据表明,对于佐剂性关节炎大鼠继发性骨质疏松模型,需要28天才能使腰椎体的骨量和强度充分降低。DU - 6712能够通过调节该关节炎模型中的骨转换来预防这些降低。